Article Text

Download PDFPDF

494 Maintenance olaparib in platinum-sensitive recurrent ovarian cancer: a comprehensive cancer centre’s experience
  1. I Moreira,
  2. M Ferreira,
  3. AR Lopes,
  4. J Savva-Bordalo,
  5. M Abreu,
  6. S Sousa and
  7. D Pereira
  1. Portuguese Institute of Oncology of Porto, Medical Oncology


Introduction/Background*The majority of newly diagnosed patients with ovarian cancer respond to platinum-based chemotherapy (ChT). However, most patients eventually relapse and will need subsequent treatment. Olaparib is a poly ADP– ribose polymerase inhibitor that has shown efficacy as maintenance treatment in patients with platinum-sensitive relapsed ovarian cancer.

Methodology We retrospectively evaluated patients with platinum-sensitive relapsed ovarian cancer treated with maintenance olaparib (400mg bid, capsules or 300mg bid, tablets), who previously received ≥2 platinum-based ChT regimens and had a partial or complete response to last platinum-based regimen. All patients were BRCA 1/2 mutated (germline and/or somatic). Study endpoints were progression-free survival (PFS), overall survival (OS), overall response rate and adverse events.

Result(s)*Between May 2016 and December 2020, 21 patients were treated with olaparib. Median age was 55 years (range 44-69), and all had ECOG ≤1. The majority had an ovary primary tumour location (81.0%) and serous histology (85.7%). Thirteen patients (61.9%) had partial response to most recent platinum-based ChT, and eight (38.1%) had complete response. Median follow-up time was 18.3 months (1.8-60.3), with 13 patients alive. Median PFS was 8.3 months (CI95% 6.0-10.6). Median OS was not reached. Overall response rate was 19.0% (4 complete responses) and 16 patients had stable disease; hence, 95.2% benefited from treatment with olaparib. There were no differences in PFS by number of prior platinum regimens, response to last platinum-based ChT, time-to-progression after penultimate platinum-based ChT (>6-12 vs >12 months) or BRCA mutation type (germline vs somatic). Most adverse events reported were grade 1 or 2 and were mainly nausea and haemathologic toxicity. Grade 3 and 4 adverse events occurred in six (28.6%) patients and were: anaemia, neutropaenia and nausea. Thirteen (61.9%) patients suspended olaparib, 12 (57.1%) due to disease progression and one due to her own will. There were no patients that suspended treatment due to toxicity.

Conclusion*Our results confirm the effectiveness and safety of maintenance olaparib in real-world setting. This treatment is feasible in the clinic and well tolerated, with manageable toxicity.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.